Therapy and Imaging of Pancreatic Carcinoma Xenografts with Radioiodine‐labeled Chimeric Monoclonal Antibody A10 and Its Fab Fragment

Takashi Kamigaki, Masahiro Yamamoto, Harumasa Ohyanagi, Masato Ohya, Takao Shimazoe, Akira Kono, Wataru Ohtani, Yuji Narita, Masahiro Ohkubo, Yoichi Saitoh

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Recombinant mouse/human chimeric monoclonal antibody A10 (ch‐A10) and its Fab fragment (ch‐Fab) react with carcinoembryonic antigen on various gastrointestinal carcinomas. We performed biodistribution studies with 125I‐labeled ch‐Al0 and ch‐Fab in an antigen‐positive human pancreatic carcinoma (BxPC‐3) xenograft model. We also evaluated the anti‐tumor effect of 131I‐labeled ch‐Al0 and studied the detection of BxPC‐3 xenografts with 123I‐labeIed ch‐Fab in whole body scintigraphy. In comparative biodistribution studies, the tumor uptake of 125I‐labeled ch‐Al0 was significantly greater than that of 125I‐labeIed ch‐Fab 24 h post‐injection. However, the tumor‐to‐blood ratio was 46.8 for ch‐Fab at 24 h post‐injection, while it was only 1.4 for ch‐Al0. Microautoradiography studies showed that ch‐Fab penetrated more uniformly into the tumor nodules than did ch‐Al0. In mice given a therapeutic dose of 131I‐labeled ch‐AlO, a significant inhibition of tumor growth was seen, while control I31l‐labeled human IgG did not affect tumor growth. Leukocyte toxicity was observed within 3 weeks after injection of 131I‐labeled ch‐Al0, but leukocyte counts recovered to normal levels at 8 weeks post‐injection. In whole‐body scintigraphy, clear and rapid tumor imaging was obtained with 200 (Ci of 123I‐labeled ch‐Fab 24 h post‐injection. These results suggest that radioiodine‐labeled chimeric A10 antibodies could potentially be useful candidates for radioimmunotherapy and radio‐immunodetection of pancreatic carcinomas.

Original languageEnglish
Pages (from-to)1216-1223
Number of pages8
JournalJapanese Journal of Cancer Research
Volume86
Issue number12
DOIs
Publication statusPublished - Dec 1995

Fingerprint

Immunoglobulin Fab Fragments
antineoplaston A10
Heterografts
Monoclonal Antibodies
Neoplasms
Radionuclide Imaging
Radioimmunodetection
Radioimmunotherapy
Therapeutics
Carcinoembryonic Antigen
Growth
Leukocyte Count
Leukocytes
Immunoglobulin G
Pancreatic Carcinoma
Carcinoma
Injections
Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Therapy and Imaging of Pancreatic Carcinoma Xenografts with Radioiodine‐labeled Chimeric Monoclonal Antibody A10 and Its Fab Fragment. / Kamigaki, Takashi; Yamamoto, Masahiro; Ohyanagi, Harumasa; Ohya, Masato; Shimazoe, Takao; Kono, Akira; Ohtani, Wataru; Narita, Yuji; Ohkubo, Masahiro; Saitoh, Yoichi.

In: Japanese Journal of Cancer Research, Vol. 86, No. 12, 12.1995, p. 1216-1223.

Research output: Contribution to journalArticle

Kamigaki, Takashi ; Yamamoto, Masahiro ; Ohyanagi, Harumasa ; Ohya, Masato ; Shimazoe, Takao ; Kono, Akira ; Ohtani, Wataru ; Narita, Yuji ; Ohkubo, Masahiro ; Saitoh, Yoichi. / Therapy and Imaging of Pancreatic Carcinoma Xenografts with Radioiodine‐labeled Chimeric Monoclonal Antibody A10 and Its Fab Fragment. In: Japanese Journal of Cancer Research. 1995 ; Vol. 86, No. 12. pp. 1216-1223.
@article{06fc5ddfae3d4514b11955ae89687761,
title = "Therapy and Imaging of Pancreatic Carcinoma Xenografts with Radioiodine‐labeled Chimeric Monoclonal Antibody A10 and Its Fab Fragment",
abstract = "Recombinant mouse/human chimeric monoclonal antibody A10 (ch‐A10) and its Fab fragment (ch‐Fab) react with carcinoembryonic antigen on various gastrointestinal carcinomas. We performed biodistribution studies with 125I‐labeled ch‐Al0 and ch‐Fab in an antigen‐positive human pancreatic carcinoma (BxPC‐3) xenograft model. We also evaluated the anti‐tumor effect of 131I‐labeled ch‐Al0 and studied the detection of BxPC‐3 xenografts with 123I‐labeIed ch‐Fab in whole body scintigraphy. In comparative biodistribution studies, the tumor uptake of 125I‐labeled ch‐Al0 was significantly greater than that of 125I‐labeIed ch‐Fab 24 h post‐injection. However, the tumor‐to‐blood ratio was 46.8 for ch‐Fab at 24 h post‐injection, while it was only 1.4 for ch‐Al0. Microautoradiography studies showed that ch‐Fab penetrated more uniformly into the tumor nodules than did ch‐Al0. In mice given a therapeutic dose of 131I‐labeled ch‐AlO, a significant inhibition of tumor growth was seen, while control I31l‐labeled human IgG did not affect tumor growth. Leukocyte toxicity was observed within 3 weeks after injection of 131I‐labeled ch‐Al0, but leukocyte counts recovered to normal levels at 8 weeks post‐injection. In whole‐body scintigraphy, clear and rapid tumor imaging was obtained with 200 (Ci of 123I‐labeled ch‐Fab 24 h post‐injection. These results suggest that radioiodine‐labeled chimeric A10 antibodies could potentially be useful candidates for radioimmunotherapy and radio‐immunodetection of pancreatic carcinomas.",
author = "Takashi Kamigaki and Masahiro Yamamoto and Harumasa Ohyanagi and Masato Ohya and Takao Shimazoe and Akira Kono and Wataru Ohtani and Yuji Narita and Masahiro Ohkubo and Yoichi Saitoh",
year = "1995",
month = "12",
doi = "10.1111/j.1349-7006.1995.tb03318.x",
language = "English",
volume = "86",
pages = "1216--1223",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Therapy and Imaging of Pancreatic Carcinoma Xenografts with Radioiodine‐labeled Chimeric Monoclonal Antibody A10 and Its Fab Fragment

AU - Kamigaki, Takashi

AU - Yamamoto, Masahiro

AU - Ohyanagi, Harumasa

AU - Ohya, Masato

AU - Shimazoe, Takao

AU - Kono, Akira

AU - Ohtani, Wataru

AU - Narita, Yuji

AU - Ohkubo, Masahiro

AU - Saitoh, Yoichi

PY - 1995/12

Y1 - 1995/12

N2 - Recombinant mouse/human chimeric monoclonal antibody A10 (ch‐A10) and its Fab fragment (ch‐Fab) react with carcinoembryonic antigen on various gastrointestinal carcinomas. We performed biodistribution studies with 125I‐labeled ch‐Al0 and ch‐Fab in an antigen‐positive human pancreatic carcinoma (BxPC‐3) xenograft model. We also evaluated the anti‐tumor effect of 131I‐labeled ch‐Al0 and studied the detection of BxPC‐3 xenografts with 123I‐labeIed ch‐Fab in whole body scintigraphy. In comparative biodistribution studies, the tumor uptake of 125I‐labeled ch‐Al0 was significantly greater than that of 125I‐labeIed ch‐Fab 24 h post‐injection. However, the tumor‐to‐blood ratio was 46.8 for ch‐Fab at 24 h post‐injection, while it was only 1.4 for ch‐Al0. Microautoradiography studies showed that ch‐Fab penetrated more uniformly into the tumor nodules than did ch‐Al0. In mice given a therapeutic dose of 131I‐labeled ch‐AlO, a significant inhibition of tumor growth was seen, while control I31l‐labeled human IgG did not affect tumor growth. Leukocyte toxicity was observed within 3 weeks after injection of 131I‐labeled ch‐Al0, but leukocyte counts recovered to normal levels at 8 weeks post‐injection. In whole‐body scintigraphy, clear and rapid tumor imaging was obtained with 200 (Ci of 123I‐labeled ch‐Fab 24 h post‐injection. These results suggest that radioiodine‐labeled chimeric A10 antibodies could potentially be useful candidates for radioimmunotherapy and radio‐immunodetection of pancreatic carcinomas.

AB - Recombinant mouse/human chimeric monoclonal antibody A10 (ch‐A10) and its Fab fragment (ch‐Fab) react with carcinoembryonic antigen on various gastrointestinal carcinomas. We performed biodistribution studies with 125I‐labeled ch‐Al0 and ch‐Fab in an antigen‐positive human pancreatic carcinoma (BxPC‐3) xenograft model. We also evaluated the anti‐tumor effect of 131I‐labeled ch‐Al0 and studied the detection of BxPC‐3 xenografts with 123I‐labeIed ch‐Fab in whole body scintigraphy. In comparative biodistribution studies, the tumor uptake of 125I‐labeled ch‐Al0 was significantly greater than that of 125I‐labeIed ch‐Fab 24 h post‐injection. However, the tumor‐to‐blood ratio was 46.8 for ch‐Fab at 24 h post‐injection, while it was only 1.4 for ch‐Al0. Microautoradiography studies showed that ch‐Fab penetrated more uniformly into the tumor nodules than did ch‐Al0. In mice given a therapeutic dose of 131I‐labeled ch‐AlO, a significant inhibition of tumor growth was seen, while control I31l‐labeled human IgG did not affect tumor growth. Leukocyte toxicity was observed within 3 weeks after injection of 131I‐labeled ch‐Al0, but leukocyte counts recovered to normal levels at 8 weeks post‐injection. In whole‐body scintigraphy, clear and rapid tumor imaging was obtained with 200 (Ci of 123I‐labeled ch‐Fab 24 h post‐injection. These results suggest that radioiodine‐labeled chimeric A10 antibodies could potentially be useful candidates for radioimmunotherapy and radio‐immunodetection of pancreatic carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=84989431522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989431522&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.1995.tb03318.x

DO - 10.1111/j.1349-7006.1995.tb03318.x

M3 - Article

C2 - 8636013

AN - SCOPUS:84989431522

VL - 86

SP - 1216

EP - 1223

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 12

ER -